164 related articles for article (PubMed ID: 24532277)
1. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Oh J; Saidha S; Cortese I; Ohayon J; Bielekova B; Calabresi PA; Newsome SD
Neurology; 2014 Mar; 82(11):984-8. PubMed ID: 24532277
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
Cortese I; Ohayon J; Fenton K; Lee CC; Raffeld M; Cowen EW; DiGiovanna JJ; Bielekova B
Neurology; 2016 Mar; 86(9):847-55. PubMed ID: 26843560
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
Giovannoni G; Kappos L; Gold R; Khatri BO; Selmaj K; Umans K; Greenberg SJ; Sweetser M; Elkins J; McCroskery P
Mult Scler Relat Disord; 2016 Sep; 9():36-46. PubMed ID: 27645341
[TBL] [Abstract][Full Text] [Related]
4. A fatal case of daclizumab-induced liver failure in a patient with MS.
Stettner M; Gross CC; Mausberg AK; Pul R; Junker A; Baba HA; Schulte-Mecklenbeck A; Wiendl H; Kleinschnitz C; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2019 Mar; 6(2):e539. PubMed ID: 30800722
[No Abstract] [Full Text] [Related]
5. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy.
Rhone EE; Cho PSP; Birring SS; Galloway J; Silber E
Mult Scler Relat Disord; 2018 Feb; 20():25-27. PubMed ID: 29276998
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal effects of daclizumab treatment of multiple sclerosis.
Bielekova B; Richert N; Herman ML; Ohayon J; Waldmann TA; McFarland H; Martin R; Blevins G
Neurology; 2011 Nov; 77(21):1877-86. PubMed ID: 22076546
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab and its use in multiple sclerosis treatment.
Milo R; Osherov M
Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
Savo AM; Book BK; Henson S; Hakimi J; Pescovitz MD
Transplant Proc; 1999; 31(1-2):1182-3. PubMed ID: 10083528
[No Abstract] [Full Text] [Related]
14. Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Reardon J; Perumal JS
Drug Des Devel Ther; 2013; 7():1187-93. PubMed ID: 24143075
[TBL] [Abstract][Full Text] [Related]
15. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab for the treatment of multiple sclerosis.
Papadopoulou A; Derfuss T; Sprenger T
Neurodegener Dis Manag; 2017 Oct; 7(5):279-297. PubMed ID: 28849702
[TBL] [Abstract][Full Text] [Related]
17. Daclizumab for relapsing remitting multiple sclerosis.
Liu J; Wang LN; Zhan S; Xia Y
Cochrane Database Syst Rev; 2013 Dec; (12):CD008127. PubMed ID: 24363032
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
[TBL] [Abstract][Full Text] [Related]
19. Daclizumab use in patients with pediatric multiple sclerosis.
Gorman MP; Tillema JM; Ciliax AM; Guttmann CR; Chitnis T
Arch Neurol; 2012 Jan; 69(1):78-81. PubMed ID: 22232346
[TBL] [Abstract][Full Text] [Related]
20. A case of immune-mediated encephalitis related to daclizumab therapy.
Devlin M; Swayne A; Newman M; O'Gorman C; Brown H; Ong B; Robertson T; Airey C; Blum S
Mult Scler; 2019 Apr; 25(5):750-753. PubMed ID: 30073905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
